Digmbio LOGO

DIGMBIO IN THE NEWS

Digmbio in the News 목록
Kim Jeongmin, CEO of DigmBio, presented Digmbio Pipeline at “BIOLEADERS CLUB”, 24th June, 2025 Kim Jeongmin, CEO of DigmBio, said, "The possibility of global technology transfer for our new drug candidate DM5167↑" Kim Jeong-min, CEO of DigmBio, disclosed the development status of the new drug candidate 'DM5167' and future technology transfer strategy at the '25th Bio Leaders Club' hosted by <News 1> on the 24th.https://www.news1.kr/bio/gene . . . READ MORE News 1 25.06.24
Kim Jeongmin, CEO of DigmBio, interviewed with the Korea Economic Daily & presented the current pipelines at the Hankyung Bioinsight monthly Interview with CEO Kim Jeong-min June 20, 2024 DM5167, a second-generation PARP inhibitor, is undergoing a phase 1 clinical trial in patients with advanced breast cancer. Partial remission was confirmed at the lowest dose.It is superior to AstraZeneca in efficacy and safety.High brain penetration rate, excellent effect on brain metastasesOptimistic abou . . . READ MORE BIO Insight 25.06.20
Digmbio, with a $12 billion investment, accelerates clinical trials of its anticancer drug DM5167 Participation in Series A rounds by Partners Invest and Medytox Venture InvestmentFocus on completing phase 1 clinical trial of selective PARP-1 inhibitorNews 1, Reporter Jin-Joong Hwang,   Digmbio, which secured 12 billion won in funding through Series A investment, is starting clinical trials for its next-generation anticancer drug candidate and . . . READ MORE News1 2025.05.30
Ministry of SMEs and Startups, 50 Baby Unicorns Selected for 2025... Half Are AI A total of 350 applicants were selected up to this year... Various benefits, including up to 300 million won in market development funds.The Ministry of SMEs and Startups announced on the 26th that it has selected 50 ‘baby unicorn’ companies with a high potential to grow into global unicorns.The Baby Unicorn Development Project is part of the "Global Unicorn . . . READ MORE Companies 2025.05.27
CEO, Jeongmin Kim’s HitNews interview Introduced Digmbio’s strategies for a novel AD drugs When I heard that CEO Kim Jeong-min, who had been recognized as a "outstanding performing researcher" in the pharmaceutical industry and had built a successful career, had suddenly decided to give up everything and launch a startup, I was more curious than just surprised. He already had experience successfully launching drugs while serving as the head of a r . . . READ MORE Hit News April 16, 2025
Digmbio secures KRW 12 billion in Series A Investment Digmbio has completed a Series A funding round of 12 billion won. This round was participated by Partners Investment, Meritz Securities, Samho Green Investment, Industrial Bank of Korea, Medytox Venture Investment, Cornerstone Partners, and Myriad Life Sciences.DM5167, currently under development by Digmbio, is a second-generation targeted anticancer drug th . . . READ MORE Financial News 2025, 03, 30
DigmBio completes Series A funding of 12 billion won for anticancer and brain disease drugs. DigmBio completes Series A funding of 12 billion won for anticancer and brain disease drugs.DigmBio announced on the 25th that it has completed a Series A funding round worth 12 billion won. DigmBio is a biotechnology company founded in 2020 by Kim Jeong-min, former head of Jeil Pharmaceutical's Central Research Institute.READ MORE This investment round . . . READ MORE Biospectator March 25, 2025
Digmbio's PARP1 Inhibitor selected by KDDF to support Phase 1 clinical trial Digmbio's PARP1 Inhibitor selected by KDDF to support Phase 1 clinical trialPhase 1 clinical development funding for HRD mutant cancer is being provided and safety and MTD to be confirmed.. The first patient dose is expected to begin this month.Digmbio announced on the 14th that it was selected as a company to receive support for Phase 1 clinical trials in t . . . READ MORE Biospectator Oct 14, 2024
DigmBio has achieved the IND approval of its selective PARP1 inhibitor by the Korea Food and Drug Administration (MFDS). . READ MORE Pharma Focus Asia March 26, 2024
DigmBio announced its selective PARP1 inhibitor has been approved by Korea Food and Drug Administration (MFDS) for IND application. . READ MORE PR News Wire March 26, 2024
DigmBio's Parkinson's disease project was recognized in 2023 as a recipient of a grant from the Korea Drug Development Fund. The Appointment of the National New Drug Development Projects in 2023 The Korea Drug Development Fund selected DigmBio's Parkinson's disease project as a recipient of a grant to further its efforts in lead optimization. Jung-Ho Kim, DigmBio's CSO, leads the project as the project manager. Click here to read Korean version READ MORE Korea Drug Development Fund April 27, 2023
DigmBio unveiled its AACR poster presentation “DM5167, a novel selective PARP1 inhibitor that effectively reduces the growth of triple-negative breast cancers . READ MORE AACR Journals April 1, 2023
Digmbio’s Alzheimer’s disease project received a grant from Korea Dementia Research Center sponsored by the Ministry of Science & ICT and the Ministry of Health & Welfare. DigmBio, led by CEO Kim Jeong-min, has been selected for the prestigious '2021 Dementia Overcoming Research and Development Project' backed by the Ministry of Science and ICT and the Ministry of Health and Welfare. Their research topic focuses on developing a new non-clinical candidate for Alzheimer's treatment targeting TASR GPCR. Their preliminary cand . . . READ MORE The Yakup May 11, 2021

검색